SMO and cancer: Mutant inactivating mutations (loss of function) in PTCH1, PTCH2, or SUFU, the activation of mutations in SMO (gain of function) or the amplification of GLI2 lead to the random activation of the expression of target genes in Hh, causing cancer [104].